Health

AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

Richard TangRichard Tangthree-minute read
Share
Portrait of Eric Lefkofsky, co-founder and chief executive of Tempus AI
Eric Lefkofsky, co-founder and chief executive of Tempus AI, whose five-year, $200 million renewal with AstraZeneca was disclosed in an 8-K filed on November 18, 2026.

Tempus AI's+0.49% — Tempus AI, up 0.49 percent today founding pharma partner just signed up for five more years, and kept an exit. An 8-K filed on November 18, 2026, discloses that AstraZeneca has committed $200 million in fees over a renewal term running January 2027 through December 2031: a $40 million annual target, a $32 million minimum in each calendar year, extendable to 2032 if the total comes up short 1.

That is the headline. The clause underneath is the story. Our earlier piece on Tempus's first profitable quarter carried the Personalis timeline and the BMS collaboration; the Fifth Amendment and its convenience clause are what changed since.

The commitment is real, but so is the exit

AstraZeneca "continues to have the right to terminate the MSA for convenience at any time." If it quits before paying the full $200 million, it owes Tempus the shortfall 1. Read plainly: AstraZeneca owes the cash even if it walks, but the amendment cannot keep it as a customer.

Tempus keeps the money and loses its flagship pharma partner, along with the strategic collaborator benefits the deal extends only while it lasts 1.

The floor is small next to what Tempus already books

Scale tells you who wins what. Tempus generated $108.1 million of Data and Applications revenue in the third quarter alone and has booked more than $550 million in data licensing so far this year, including October's BMS collaboration: $137.5 million of oncology licensing plus $55 million for a BMS and Pathos license to its Alzheimer's and dementia data 2.

Two BMS licenses are about a third of Tempus's 2026 data licensing

  • BMS oncology licensing, $137.5M137.525%
  • BMS and Pathos dementia license, $55M5510%
  • All other 2026 licensing, $357.5M357.565%
Data
SliceValueShare
BMS oncology licensing, $137.5M137.525%
BMS and Pathos dementia license, $55M5510%
All other 2026 licensing, $357.5M357.565%
Tempus's data licensing booked so far in 2026, in millions of US dollars. The draft gives more than $550 million for the year, of which $137.5 million is oncology licensing and $55 million is a BMS and Pathos license to Alzheimer's and dementia data; everything else is grouped as other. Source: Tempus third-quarter 2026 results [2].2

The $32 million yearly minimum is a fraction of one quarter of that segment's revenue 12. So the commitment de-risks Tempus's 2027 bookings line without making it dependent, and the concentration risk runs both ways: Tempus loses its largest pharma relationship if AstraZeneca walks, while AstraZeneca holds five years of optionality over an AI data supplier for the price of a shortfall payment 12.

A single quarter of Tempus revenue tops the whole five-year AstraZeneca pledge

$0.1B$0.2B$0.3B$0.4B$0.5BQ1 '24Q3 '24Q1 '25Q3 '25Q1 '26Q3 '26$0.41B
Data
Revenue
Q4 '23$0.15B
Q1 '24$0.15B
Q2 '24$0.17B
Q3 '24$0.18B
Q4 '24$0.2B
Q1 '25$0.26B
Q2 '25$0.32B
Q3 '25$0.33B
Q4 '25$0.37B
Q1 '26$0.35B
Q2 '26$0.38B
Q3 '26$0.41B
Tempus AI total quarterly revenue, Q4 2023 through Q3 2026, in US dollars. Source: Tempus AI quarterly figures from its SEC filings, retrieved November 18, 2026 [4].4

The filing lands twelve days before the Personalis vote

The filing lands twelve days before Personalis shareholders vote on November 30 to approve Tempus's acquisition of their company, a cash-and-stock merger anchored at $16.25 per Personalis share that a law firm is already investigating over price 23. Tempus is paying partly in its own stock, so anything that supports the quality of its committed revenue touches the currency of the deal.

Whether the amendment actually moves those voters is unproven; what the contract shows is that bookings are now written as a five-year minimum with a make-whole. What to watch next: whether AstraZeneca spends toward its $40 million annual target or drifts to the $32 million floor 1, and how the November 30 meeting prices the difference.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading TEM

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

    Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Health

    OpenAI prices healthcare back-office work at 8.5 cents a task, undercutting Ambience Healthcare

    OpenAI's new healthcare agents run prior-authorization work at 8.5 cents a task, and Menlo Ventures says the scribe market's new dollars are going to Microsoft and Epic. Ambience's $37,500-per-doctor receipt is now the only thing it sells that the model layer does not.

    Health

    Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

    The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Subscribe to TheInference for free